Javier Ortiz

Javier Ortiz

Auto-generated profile, based on publicly available information

Javier Ortiz

Pathology Service of the University Hospital of Salamanca, Cell Biology and Pathology Department, Paseo de la Transición Española, 37007 Salamanca, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJuan Garcia
Juan Garcia
MPMaria Perez-Caro
Maria Perez-Caro
JGJuan A Gomez-Moreta
Juan A Gomez-Moreta
FGFrancisco Gonzalez
Francisco Gonzalez
JOJavier Ortiz
Javier Ortiz
Manuel Adolfo Sanchez-MartinManuel Adolfo Sanchez-Martin
Manuel Adolfo Sanchez-Martin
Background: Gliomas are the most common type of primary brain tumours, and in this group glioblastomas (GBMs) are the higher-grade gliomas with fast progression and unfortunate prognosis. Two major aspects of glioma biology that contributes to its awful prognosis are the formation of new blood vessels through the process of angiogenesis and the invasion of glioma cells. Despite of advances, two-year survival for GBM patients with optimal therapy is less than 30%. Even in those patients with low-grade gliomas, that imply a moderately good prognosis, treatment is almost never curative. Recent studies have demonstrated the existence of a small fraction of glioma cells with characteristics of neural stem cells which are able to grow in vitro forming neurospheres and that can be isolated in vivo using surface markers such as CD133. The aim of this study was to define the molecular signature of GBM cells expressing CD133 in comparison with non expressing CD133 cells. This molecular classification could lead to the finding of new potential therapeutic targets for the rationale treatment of high grade GBM. Methods: Eight fresh, primary and non cultured GBMs were used in order to study the gene expression signatures from its CD133 positive and negative populations isolated by FACS-sorting. Dataset was generated with Affymetrix U133 Plus 2 arrays and analysed using the software of the Affymetrix Expression Console. In addition, genomic analysis of these tumours was carried out by CGH arrays, FISH studies and MLPA; Results: Gene expression analysis of CD133+ vs. CD133- cell population from each tumour showed that CD133+ cells presented common characteristics in all glioblastoma samples (up-regulation of genes involved in angiogenesis, permeability and down-regulation of genes implicated in cell assembly, neural cell organization and neurological disorders). Furthermore, unsupervised clustering of gene expression led us to distinguish between two groups of samples: those discriminated by tumour location and, the most importantly, the group discriminated by their proliferative potential; Conclusions: Primary glioblastomas could be sub-classified according to the properties of their CD133+ cells. The molecular characterization of these potential stem cell populations could be critical to find new therapeutic targets and to develop an effective therapy for these tumours with very dismal prognosis.

Verified
Journal Article
Open access
PDF file
Patricia Alejandra GarridoPatricia Alejandra Garrido
Patricia Alejandra Garrido
MGMaría González-Tablas
María González-Tablas
APAlejandro Pasco Peña
Alejandro Pasco Peña
MHMaría Victoria Zelaya Huerta
María Victoria Zelaya Huerta
JOJavier Ortiz
Javier Ortiz
MTMaría Dolores Tabernero
María Dolores Tabernero
Rhabdoid meningiomas (RM) shows heterogeneous histological findings, and a wide variety of chromosomal copy number alterations (CNA) are associated with an unpredictable course of the disease. In this study, we analyzed a series of 305 RM samples from patients previously reported in the literature and 33 samples from 23 patients studied in our laboratory. Monosomy 22-involving the minimal but most common recurrent region loss of the 22q11.23 chromosomal region was the most observed chromosomal alteration, followed by losses of chromosomes 14, 1, 6, and 19, polysomies of chromosomes 17, 1q, and 20, and gains of 13q14.2, 10p13, and 21q21.2 chromosomal regions. Based on their CNA profile, RM could be classified into two genetic subgroups with distinct clinicopathologic features characterized by the presence of (1) chromosomal losses only and (2) combined losses and gains of several chromosomes. The latter displays a higher frequency of WHO grade 3 tumors and poorer clinical outcomes.

13 December 2002 in Cytopathology
Verified
Journal Article
Closed access
PDF file
JOJ. Ortiz
J. Ortiz
MAM. Abad
M. Abad
MMM. Muriel
M. Muriel
DFD. Fernández
D. Fernández
ABA. Bullón
A. Bullón

4 September 2008 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
JOJavier Ortiz
Javier Ortiz
AOAlvaro Otero
Alvaro Otero
OBOscar Bengoechea
Oscar Bengoechea
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
PSPablo Sousa
Pablo Sousa
ABAgustín Bullón
Agustín Bullón
We report a divergent ependymal tumor of the posterior fossa (ependymoblastoma/anaplastic ependymoma) observed in an 8-year-old boy. The tumor showed the histological pattern typical of an ependymoblastoma (tubular-papillary fetaloid architecture with stratification of the tumor cells) next to areas in which findings typical of an anaplastic ependymoma were detected. The immunohistochemical study confirmed our diagnostic suspicion, allowing us to establish a differential diagnosis with other entities such as medulloblastoma, medulloepithelioma, atypical rhabdoid/teratoid tumor, or metastases.

9 December 2013 in Neuropathology
Verified
Journal Article
Closed access
PDF file
JOJavier Ortiz
Javier Ortiz
SCSofia del Carmen
Sofia del Carmen
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
ECEliseo Carrascal
Eliseo Carrascal

26 January 2004 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
JOJ. Ortiz
J. Ortiz
MAM. Abad
M. Abad
ABA. Bullón
A. Bullón
IGI. García
I. García